- New England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia
- Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
- Acceleron to Participate in Two Upcoming Healthcare Investor Conferences
- Acceleron to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on February 27, 2020
- Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension
- Acceleron Announces Change to Executive Management Team
- New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial
- Acceleron to Participate in the 38th Annual J.P. Morgan Healthcare Conference
Acceleron Pharma Inc (XLRN:NMQ) closed at 89.87, -7.88% below its 52-week high of 97.56, set on Mar 03, 2020.
37.01Jun 11 201997.56Mar 03 2020
Markit short selling activity
|Market cap||4.56bn USD|
|EPS (TTM)||-2.39 |
Data delayed at least 15 minutes, as of Mar 31 2020 21:00 BST.